U.S. FDA panel recommends approval of Johnson & Johnson’s depression drug

Share this post

An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson’s experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply